Approaches and Challenges in SARS-CoV-2 Vaccine Development
Open accessAbstract
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some vaccines may not protect against viral acquisition and infection of the oral-nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.
“They strengthen the hypothesis that some vaccines may not protect against viral acquisition and infection of the oral-nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [37]
Results are in line with nonhuman primate data showing that vaccinated and challenged animals have detectable viral loads in nasal swabs but not in lower airways.
“Our results are in line with those obtained in nonhuman primates, in which vaccinated and then challenged animals display detectable viral loads in nasal swabs but not in lower airways 37 .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 102 · Cited by 103
- Authors
- Dagotto, G., Yu, J., & Barouch, D. H.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Barouch, Dan H.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 28
- Issue
- 3
- Pages
- 364-370
- ISSN
- 1931-3128 (ISSN-L)
- PMC
- PMC7416703
- OpenAlex
- W3048160337
- Cited by
- 103
- References
- 102
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 12 · 2022: 25 · 2021: 52 · 2020: 7
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Host & Microbe (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bill and Melinda Gates Foundation (INV-006131)
- National Institutes of Health (OD024917, 62/994,630, 62/969,008, AI126603, AI124377, AI129797, AI128751)
- Ragon Institute of MGH, MIT and Harvard
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 vaccine development, vaccine candidate, antigen selection, preclinical vaccine evaluation, correlates of protection
- MeSH terms
- Betacoronavirus, Host Microbial Interactions, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Antigens, Viral, Humans, Immunity, Cellular, Immunity, Innate, Pneumonia, Viral, Primates, Viral Vaccines, Coronavirus Infections, Models, Animal, Immunity, Humoral, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
